A randomised, placebo-controlled, double-blind phase III study of sequential administration of Tarceva (erlotinib) or placebo in combination with gemcitabine/platinum as first-line treatment in patients with stage IIIB/V non-small cell lung cancer (NSCLC)

Project Title	A randomised, placebo-controlled, double-blind phase III study of sequential administration of Tarceva (erlotinib) or placebo in combination with gemcitabine/platinum as first-line treatment in patients with stage IIIB/V non-small cell lung cancer (NSCLC)
Principal Investigator	Ho, James Chung Man (Principal investigator)
Co-Investigator(s)	Dr Wang Julie Kwan Ling (Co-Investigator) Dr Lam David Chi Leung (Co-Investigator) Dr Wong Matthew King Yan (Co-Investigator) Dr Lam Jamie Chung Mei (Co-Investigator)
Funding Year	2008/2009
Amount	358317
Panel	Medicine
Start Date	01-04-2009
Expected Completion	31-08-2013
Status	On-going
Keywords	stage IIIB/V NSCLC
Discipline	Respiration, Cancer
Grant Type/Funding Scheme	Pharmaceutical Industry - General Award
Duration	53

Project Title

Principal Investigator

Ho, James Chung Man (Principal investigator)

Co-Investigator(s)

Dr Wang Julie Kwan Ling (Co-Investigator)
Dr Lam David Chi Leung (Co-Investigator)
Dr Wong Matthew King Yan (Co-Investigator)
Dr Lam Jamie Chung Mei (Co-Investigator)

Funding Year

2008/2009

Amount

358317

Panel

Medicine

Start Date

01-04-2009

Expected Completion

31-08-2013

Status

On-going

Keywords

stage IIIB/V NSCLC

Discipline

Respiration, Cancer

Grant Type/Funding Scheme

Pharmaceutical Industry - General Award

Duration

53

Grant: A randomised, placebo-controlled, double-blind phase III study of sequential administration of Tarceva (erlotinib) or placebo in combination with gemcitabine/platinum as first-line treatment in patients with stage IIIB/V non-small cell lung cancer (NSCLC)